Use of mycophenolate in the treatment of autoimmune hepatitis

Liver International

Volumn 25, Issue 4, 2005, Pages 687-691

  Oo, Y H ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DEFLAZACORT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISOLONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ABDOMINAL DISCOMFORT; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BLOOD DISEASE; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE CLASSIFICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; EDITORIAL; FIRST PASS EFFECT; GASTROINTESTINAL DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PANCREATITIS; RECURRENT DISEASE; REMISSION; SKIN DISEASE; VOMITING;

HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 22844449643     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01123.x     Document Type: Editorial

References (44)

1. Alverez F, Berg P A, Bianchi F B. International Autoimmune hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
2. Gregorio G V, Portmann B, Reid F, Donaldson P T, Doherty D G, Mccartney M, Mowat A P, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-7.
3. Donaldson P T, Doherty D G, Hayllar K M, McFarLane I G, Johnson P J, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leucocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-6.
4. Strettell M D, Donalson P T, Thomson L J, San-Trach P J, Moore S B, Czaja A J, Williams R. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 2028-35.
5. Czaja A J, Manns M P, McFarlane I G, et al. Autoimmune hepatitis: the investigation and clinical challenge. Hepatology 2000; 31: 1194-200.
6. Krawitt E L. Autoimmune hepatitis. N Engl J of Med 1996; 334: 897-903.
7. Murray Lyon I M, Stern R B, Williams R. Controlled trial of prednisolone and azathioprine in active chronic hepatitis. Lancet 1973; 2: 735-7.
8. Mackay I R, Wood T J. Lupoid hepatitis: a comparism of 22 cases with other types of liver disease. Q J Med 1962; 31: 485-507.
9. Cook G C, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.
10. Soloway R D, Summerskill W H J, Baggenstoss A H, Geall M G, Gitnick G L, Elveback I R, et al. Clinical, biochemical and histological remission of severe chronic active liver disease: a controlled study of treatment and early prognosis. Gastroenterology 1972; 63: 820-33.
11. Copenhagen Study Group for Liver Diseases. Effect of prednisolone on the survival of patients with cirrhosis of liver. Lancet 1969; i: 119-2.
12. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis 2002; 22(4): 379-86.
13. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transplant Surg 1995; 1(5 Suppl. 1): 109-15.
14. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984; 37(4): 363-5.
15. Milkiewicz P, Hubscher S G, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68(2): 253-6.
16. Johnson PJ, McFarlane I G, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
17. Szefler S J. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol 1999; 104(4 Part 2): 175-83.
18. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8(6): 585-90.
19. Czaja A J, Lindor K D. Failure of budesonide in a pilot study of treatment-dependant autoimmune hepatitis. Gastroenterology 2000; 119: 1312-6.
20. Deflazacort - an alternative to prednisolone? Drug Ther Bull 1999; 37: 57-8.
21. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis. Rev Esp Enferm Dig 1999; 91: 630-8.
22. Hyams J S, Ballow M, Leichtner A M. Cycolsporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-3.
23. Sherman K E, Narkewicz M, Pinto P C. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
24. Van Thiel D H, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-6.
25. Kanzlar S, Gerken G, Dienes H P, Meyer Zum Buschenfelde K H, Lohse A W. Cyclophosphamide as alternative immunosupression therapy for autoimmune hepatitis-report of three cases. Z Gastroenterol 1997; 35: 571-8.
26. Pratt D S, Flavin D P, Kaplan M M. The Successful Treatment of autoimmune hepatitis with 6-mercaptourine after failure with azathioprine. Gastroenterology 1996; 110: 271-4.
27. Stern R B, Wilkinson S P, Howarth P J N, Williams R. Controlled trial of synthetic D-penicillamine and prednisolone in maintainance therapy for chronic hepatitis. Gut 1997; 18: 19-22.
28. McClements B M, Callender M E. D-penicillamine therapy in patients with HbsAg-negative chronic active hepatitis and major prednisolone-induced adverse effects. J Hepatol 1990; 11: 322-5.
29. Burak K W, Urbanski S J, Swain M G. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29(6): 990-3.
30. Venkataramani A, Jones M B, Sorrell M F. Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastroenterol 2001; 96(12): 3432-4.
31. Czaja A J, Carpenter H A, Lindor K D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomised placebo-controlled treatment trial. Hepatology 1999; 30: 1381-6.
32. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-5.
33. Flourey H W, Gilliver K, Jennings M A, Saunder A G. Mycophenolic acid: an antibiotic from Penicillium Brevicompactum Dierckx. Lancet 1946; 250: 46-9.
34. Sollinger H W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate mofetil Study Group. Transplantation 1995; 60: 225-32.
35. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321-5.
36. Matthew T H. A blinded,long-term randomised multi-centred study of mycophenolate mofetil in cadeveric renal transplantation. Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450-4.
37. Eckhoff D E, McGuire B M, Frenette L R, et al. Tacrolimus and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65: 180-7.
38. Kobashigawa J M L, Renlund D, Mentzer R, et al. A randomised active controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-15.
39. Allison A C, Eugui E M. Immunosupressive and other effects of mycophenolic acid and an ester produrg, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28.
40. Gummert J F, Ikonen T, Morris R E. Newer immunosuppressive drugs: review. J Am Soc Nephrol 1999; 10: 1366-80.
41. Richardson P D, James P D, Ryder S D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5.
42. Devlin S M, Swain M G, Urbanski S J, Burak K W. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-5.
43. Schuppan D, Herold C, Strobel D, Schneider H T, Hahn E G. Successful treatment of therapy-refractory autoimmune hepatitis with mycophenolate mofetil. Hepatology 1998; 28: A1960.
44. Chatur N, Ramji A, Bain V G, Ma M M, Marotta P J, Ghent C N, Lilly L B, Heathcote E J, Deschenes M, Lee S S, Steinbrecher U P, Yoshida E M. Transplant immunosupressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and Tacrolimus. Liver Int 2005; 25: 723-27.